Investor relations

Investor relations

Our science-led strategy is key to delivering long-term value for patients, employees and shareholders.

NYSE: MRK
October 23, 2021 5:45 am ET
Delayed at least 20 minutes

Latest news, events & financials

October 22, 2021

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC)

October 20, 2021

CDC ACIP Unanimously Votes to Provisionally Recommend Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Series with PNEUMOVAX ® 23 (Pneumococcal Vaccine Polyvalent) as an Option for Pneumococcal Vaccination in Appropriate Adults

October 19, 2021

Merck Issues Voluntary Nationwide Recall of CUBICIN® (daptomycin for injection) 500 mg, Lot 934778, Due to Presence of Particulate Matter Identified as Glass Particles

View all

October 28, 2021

Earnings

Merck & Co., Inc. Q3 2021 Earnings Call

Add to Calendar Webcast

February 03, 2022

Earnings

Merck & Co., Inc. Q4 2021 Earnings Call

Add to Calendar

April 28, 2022

Earnings

Merck & Co., Inc. Q1 2022 Earnings Call

Add to Calendar

July 28, 2022

Earnings

Merck & Co., Inc. Q2 2022 Earnings Call

Add to Calendar

View all

2Q21 Merck Earnings Announcement
PDF

2Q21 Merck Other Financial Disclosures
PDF

View all

Merck & Co., Inc. Q3 2021 Earnings Call

Dial: (833) 353-0277 or (469) 886-1947
Access Code: 6768456

Add to Calendar

Webcast

See full agenda

Our pipeline shows our relentless pursuit of the next breakthrough.

Explore our pipeline

Phase II programs

Phase III programs

Under review

Our leadership

Our deep bench of talent has the knowledge, commitment and expertise to successfully execute on our innovation strategy.

Leadership

Corporate responsibility

Supporting the future of our business and the health and well-being of patients, people and communities around the world.

Download our 2020/2021 ESG Progress Report

We're led by our science

We follow the science to our next breakthrough, leaving no stone unturned.

View our stories

Innovation

Our second-quarter 2021 financial results

Merck announced second-quarter 2021 sales from continuing operations (excluding Organon) of $11.4 billion, 22% above second-quarter 2020. Excluding the impact from foreign exchange, sales grew 19%. The company anticipates full-year 2021 revenue range to be between $46.4 billion and $47.4 billion, including a positive impact from foreign exchange of less than 2%. Take a look […]

Next: Our second-quarter 2021 financial results